Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Tung v. Bristol-Myers Squibb Company et al
Case Number:
1:18-cv-01611
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Bernstein Litowitz
- Bleichmar Fonti
- Grant & Eisenhofer
- Kirkland & Ellis
- Labaton Keller
- Motley Rice
- Pomerantz LLP
Companies
Sectors & Industries:
-
March 11, 2022
2nd Circ. Backs Dismissal of Bristol-Myers Clinical Trial Suit
The Second Circuit on Friday agreed with a New York federal court that investors hadn't shown that Bristol-Myers hid information about patients in a clinical trial for a new lung cancer drug, holding that the shareholders failed to allege a material misstatement or omission made by the company.
-
October 01, 2020
Bristol-Myers Squibb Escapes Investor Suit Over Clinical Trial
For the second and final time, a New York federal judge on Wednesday dismissed an investor suit against Bristol-Myers Squibb that alleged the pharmaceutical company hid information about patients in a clinical trial for a new lung cancer drug, saying the investors again didn't show the company or its executives misled them.
-
September 11, 2018
Bristol-Myers Looks To Ax Investor Suit Over Clinical Trial
Bristol-Myers Squibb asked a New York federal judge on Tuesday to toss a proposed class action alleging it misled investors about the clinical trial patients for its new lung cancer drug, saying the investors have yet to show a material misstatement or omission made by the company.